A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

PHASE3CompletedINTERVENTIONAL

Enrollment

299

Participants

Timeline

Start Date

December 19, 2005

Primary Completion Date

August 15, 2008

Study Completion Date

August 15, 2008

Conditions

Hepatic Encephalopathy

Interventions

DRUG

Rifaximin

Oral

DRUG

Placebo

Oral

All Listed Sponsors

lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00298038 - A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy | Biotech Hunter | Biotech Hunter